LDE225 + BKM120
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dose Escalation
Conditions
Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Trial Timeline
Jul 1, 2012 → Apr 1, 2015
NCT ID
NCT01576666About LDE225 + BKM120
LDE225 + BKM120 is a phase 1 stage product being developed by Novartis for Dose Escalation. The current trial status is completed. This product is registered under clinical trial identifier NCT01576666. Target conditions include Dose Escalation, Safety, Preliminary Efficacy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01576666 | Phase 1 | Completed |
Competing Products
6 competing products in Dose Escalation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E3810 + E3810 + Teprenone | Eisai | Phase 2/3 | 65 |
| Rabeprazole + Rabeprazole | Eisai | Phase 2/3 | 65 |
| mRNA-2752 + Durvalumab | AstraZeneca | Phase 1 | 33 |
| Carbidopa/levodopa/entacapone | Novartis | Approved | 85 |
| ETC-1002 | Esperion Therapeutics | Phase 1 | 28 |
| AUTO CAR T cell therapy | Autolus Therapeutics | Phase 2 | 44 |